CLAIMS

1. (currently amended) A composition including an effective amount of the polypeptide EEIIMD in the range of 2 μM to 10 μM, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity ~~without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute maycardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis~~.

2. (original) The composition acoording to claim 1, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.

3. (cancelled)

4. (cancelled)

5. (cancelled)

6. (cancelled)

7. (currently amended) A method of enhancing the fibrinolytic activity of a fibrinolytic agent, said method comprising administering <u>in vitro</u> an effective amount of the polypeptide EEIIMD in the range of 2 uM to 10 uM, <u>to enhance the activity</u> ~~and a suitable amount of~~ <u>a suitable amount</u> of a fibrinolytic agent to induce the desired level of fibrinolytic activity ~~without causing cranial hemorrhage in a subject suffering from ischemic stroke, acute maycardial infarction, pulmonary emboli, peripheral artery disease or deep vein thrombosis~~.

8. (original) The method according to claim 7, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.

9. (cancelled).

10. (cancelled).